SCHEMBL4408510

SCHEMBL4408510

O=c1cc(-c2ccc(OCc3ccccc3)c(OCc3ccccc3)c2)oc2cc(OCC3CO3)ccc12

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 1/20 0.52
CYP1A2 P05177 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.50
PRKDC P78527 1/20 0.47
ABCB1 P08183 1/20 0.47
MAOB P27338 4/20 0.46
TDP1 Q9NUW8 3/20 0.46
NPC1 O15118 1/20 0.46
MAOA P21397 1/20 0.46
CASP3 P42574 1/20 0.46
RAB9A P51151 1/20 0.46
SENP8 Q96LD8 1/20 0.46
SENP7 Q9BQF6 1/20 0.46
SENP6 Q9GZR1 1/20 0.46
ACHE P22303 2/20 0.46
TERT O14746 1/20 0.46
SIGMAR1 Q99720 1/20 0.45
BCHE P06276 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4405430 0.93 CYP1A1 (0.51) CYP1A1CYP1A2L3MBTL1ABCB1MAOB
SCHEMBL1483628 0.87 PRKDC (0.52) L3MBTL1PRKDCABCB1MAOBTDP1
SCHEMBL1483630 0.87 PRKDC (0.52) L3MBTL1PRKDCABCB1MAOBTDP1
SCHEMBL1483626 0.87 PRKDC (0.52) L3MBTL1PRKDCABCB1MAOBTDP1
SCHEMBL10486553 0.84 TNKS (0.61) SIGMAR1
SCHEMBL4166843 0.84 CYP1A1 (0.55) CYP1A1CYP1A2L3MBTL1ABCB1MAOB
SCHEMBL4161823 0.84 ABCB1 (0.67) CYP1A1CYP1A2L3MBTL1ABCB1MAOB
SCHEMBL7683484 0.83 CYP1A1 (0.54) CYP1A1CYP1A2L3MBTL1MAOBMAOA
SCHEMBL4410884 0.83 CYP1A1 (0.54) CYP1A1CYP1A2L3MBTL1MAOBMAOA
SCHEMBL14293137 0.83 TNKS (0.53) L3MBTL1PRKDCMAOBTDP1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1807408-B1 OXY SUBSTITUTED FLAVONES AS ANTIHYPERGLYCEMIC AND ANTIDYSLIPIDEMIC AGENTS COUNCIL SCIENT IND RES (IN) 2016-06-08 EP disclosed
US-7635779-B2 Oxy substituted flavones as antihyperglycemic and antidyslipidemic agents COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2009-12-22 US disclosed
EP-1807408-A1 OXY SUBSTITUTED FLAVONES AS ANTIHYPERGLYCEMIC AND ANTIDYSLIPIDEMIC AGENTS Council of Scientific and Industrial Research (IN) 2007-07-18 EP disclosed
US-20060178373-A1 Oxy substituted flavones as antihyperglycemic and antidyslipidemic agents COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2006-08-10 US disclosed
WO-2006040621-A1 OXY SUBSTITUTED FLAVONES AS ANTIHYPERGLYCEMIC AND ANTIDYSLIPIDEMIC AGENTS COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2006-04-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178373-A1 Oxy substituted flavones as antihyperglycemic and antidyslipidemic agents GPR119, LIPC, SLC5A2 CYP1A1 584/4885CYP1A2 136/4885L3MBTL1 2239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.